Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSTAT versus EVEKEO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSTAT versus EVEKEO ODT.
DEXTROSTAT vs EVEKEO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextroamphetamine is a central nervous system stimulant that promotes release of dopamine and norepinephrine from presynaptic neurons, and inhibits their reuptake, thereby increasing synaptic concentrations of these neurotransmitters.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
5-60 mg orally per day in divided doses, typically 5-10 mg 2-3 times daily, maximum 60 mg/day.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
None Documented
None Documented
Terminal elimination half-life is approximately 10-13 hours in adults, 6-8 hours in children. Extended duration allows once-daily dosing in some patients.
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Primarily renal (approximately 90% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Category C
Category C
CNS Stimulant
CNS Stimulant